Salix Coronary Plaque vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Salix Coronary Plaque

by Artrya Limited

EchoNext

by Pathway Labs

AI Verdict

Both tools are FDA-cleared AI solutions focused on cardiology, but they address different diagnostic stages and utilize distinct input data. Salix Coronary Plaque analyzes CCTA scans to assess coronary artery plaque and stenosis, providing detailed anatomical information. EchoNext, on the other hand, screens for hidden structural heart disease, including heart failure and valve disease, by analyzing standard ECGs, making it a broader initial screening tool.

Choose Salix Coronary Plaque if…

Choose Salix Coronary Plaque if your cardiology or radiology department needs near real-time, AI-driven analysis of CCTA scans to assess coronary artery plaque and stenosis. This tool is ideal for rapidly diagnosing coronary artery disease, identifying high-risk plaque features, and quantifying calcifications to aid in personalized treatment and preventative care.

View Salix Coronary Plaque →

Choose EchoNext if…

Choose EchoNext if your practice or hospital aims to screen a broad patient population for hidden structural heart disease using standard ECGs. This AI tool is particularly well-suited for early detection of conditions like heart failure, valve disease, and pulmonary hypertension, especially when a cost-effective and non-invasive initial screening is desired to identify patients who may require further evaluation with an echocardiogram.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Salix Coronary Plaque	EchoNext
Pricing	Contact for pricing	Starts at $600/month
Deployment	Cloud	Available through the OpenEvidence clinical decision support platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	Yes AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Salix Coronary Plaque

Salix Coronary Plaque is described as a web-based software offering near real-time assessment and automated report generation, suggesting a streamlined workflow. Its integration into existing workflows and minimal training requirements also point to strong usability.

Clinical Value

EchoNext

EchoNext has demonstrated superior diagnostic accuracy compared to cardiologists in studies, identifying structural heart problems from ECGs more often. It also has a broader range of detection, flagging six conditions including heart failure, valve disease, and pulmonary hypertension.

Pricing & Value

EchoNext

EchoNext offers tiered pricing starting at $600/month, providing transparency and options for different organizational sizes. Salix Coronary Plaque's 'contact for pricing' model, while having a high CPT reimbursement rate, lacks initial transparency.

Enterprise Readiness

EchoNext

EchoNext explicitly states HIPAA compliance and offers a Business Associate Agreement (BAA). Its deployment through the OpenEvidence platform, used by 650,000 U.S. physicians, indicates significant scalability and integration capabilities.

Innovation

EchoNext

EchoNext is highlighted as the world's first FDA-approved AI detection tool to analyze ECGs for hidden structural heart disease, a significant breakthrough. It also demonstrates superior accuracy compared to cardiologists, even those assisted by AI.

Support & Docs

Tie

Neither tool provides explicit details on their support and documentation offerings in the provided information. Therefore, it is not possible to definitively pick a winner in this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Salix Coronary Plaque	EchoNext
Product Name	Salix Coronary Plaque	EchoNext
Company	Artrya Limited	Pathway Labs
Description	FDA-cleared, AI-driven, web-based software that provides near real-time, point-of-care assessment of coronary artery plaque and stenosis from CCTA scans, aiding in the rapid and accurate diagnosis of coronary artery disease.	FDA-cleared AI tool that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Primary Input	CCTA scans	Standard ECGs
Key Detections	Coronary artery plaque (atherosclerosis), stenosis, high-risk plaque features (e.g., low-attenuation plaque, spotty calcification, positive remodeling, napkin-ring sign), calcifications (calcium scoring).	Hidden structural heart disease, heart failure, valve disease, pulmonary hypertension indicators.

Videos

Demos, reviews, and walkthroughs featuring Salix Coronary Plaque and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate with existing EHR systems and what is the depth of that integration?

Salix Coronary Plaque offers integrated workflow management and automated report generation, which can likely be exported and manually or semi-automatically imported into an EHR. EchoNext is available through the OpenEvidence clinical decision support platform, suggesting its integration capabilities would be mediated through that platform, potentially offering deeper integration for ECG data and decision support within existing clinical workflows.

What is the typical learning curve for physicians and their teams to effectively utilize each tool in their daily practice?

Salix Coronary Plaque, being a web-based software for CCTA analysis with automated report generation, may have a moderate learning curve primarily focused on interpreting the AI-generated reports and integrating them into existing CCTA reading workflows. EchoNext, which analyzes standard ECGs, might have a relatively lower learning curve for physicians already familiar with ECG interpretation, as it provides AI-powered insights on existing diagnostic data.

Beyond HIPAA, what are the key security features and data governance practices for each tool?

While both tools are expected to adhere to HIPAA, Salix Coronary Plaque's description focuses on its AI capabilities and workflow, without explicitly detailing additional security features. EchoNext, being available through the OpenEvidence platform, would likely leverage the security posture of that platform, which typically includes robust data encryption, access controls, and audit trails to protect patient information.

Can these tools be effectively rolled out across multiple clinical sites or a large hospital system, and what considerations should be made?

Salix Coronary Plaque's web-based deployment suggests good scalability for multi-site rollouts, with considerations for consistent CCTA scan acquisition protocols and standardized interpretation across sites. EchoNext's availability through the OpenEvidence platform, designed for broad access from major hospitals to community practices, indicates it is well-suited for multi-site deployments, with considerations for platform integration and user training across different clinical environments.

What kind of customer support is available for each tool, and what is the typical response time for critical issues?

The provided information does not explicitly detail the specifics of customer support for either Salix Coronary Plaque or EchoNext, such as support hours, channels, or guaranteed response times. Physicians would need to inquire directly with Artrya Limited and Pathway Labs for detailed information on their support offerings and service level agreements.

How do the accuracy and sensitivity of each tool compare to current gold standards or expert human interpretation in their respective domains?

Salix Coronary Plaque provides near real-time, point-of-care assessment of coronary artery plaque and stenosis from CCTA scans, aiding in rapid and accurate diagnosis, implying high accuracy in detecting and quantifying plaque and stenosis. EchoNext analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, suggesting its accuracy lies in identifying these conditions from ECG data, which traditionally requires more advanced imaging or clinical assessment.